Small Cap Feast
Small Cap Feast – 26 July 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Interswitch, a Nigeria-based payments firm, has hired advisers to resurrect plans for a stock-market listing in London and Lagos later this year, which may value the financial technology company at $1.3 billion to $1.5 billion.
Roxi Music UK music streaming service plans London IPO as it goes up against Spotify. They have appointed investment bank Arden Partners for an initial public offering (IPO) on the London Stock Exchange later this year.
Freyherr International Group PLC the Medicinal Cannabis holding company established in 2016, is planning to list on the NEX exchange on the 30th July
Mulberry Group (MUL.L) 263p £157.9m
The British luxury brand, announced the acquisition on 24 July 2019 of the minority interest in the share capital of Mulberry Korea, the Group’s business in South Korea
The Group has acquired 40% of the share capital of Mulberry Korea previously held by its local partner, SHK Holdings Limited
Mulberry Korea is now a wholly owned subsidiary of the Group
Additional investment made in Mulberry Korea is £1.3m
Together with its initial investment of £3.1m made during Aug 2018, this brings the Group’s total investment in Mulberry Korea to £4.4m
The Acquisition is in line with the Group’s international development strategy
Motif Bio (MTFB.L) 2.58p £8.84m
The clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that the U.S. FDA has granted the Company’s request for a Type B meeting related to a proposed clinical study for the Company’s lead product candidate, iclaprim. The in person meeting has been scheduled for Sept 19, 2019.
As previously announced, Motif Bio submitted a meeting request and clinical study proposal to the FDA based upon the minutes from a May 3, 2019, Type A meeting with the Agency, which indicated that an additional clinical trial will be required prior to granting marketing approval for iclaprim. The Company was encouraged by the FDA to put forth a proposal for such a study, and Motif Bio plans to discuss the proposed patient population and study design with the Agency at the upcoming meeting.
Block Energy (BLOE.L) 8.6p £42.31m
Resumption of Production at West Rustavi. Production resumed on 11 July and since testing began the Well has produced at an average rate of approximately 360 boepd (295 bopd plus 390 Mcf/d) on varying choke sizes, with an average water cut of 25%, considered to be mainly returned drilling fluid.
A minimum of 1,200 barrels of drilling fluid were lost to the Well during drilling and completion operations, a considerable amount indicative of the high productivity of the fractures system. Estimates of the volume of water produced and observations of polymer and other drilling fluid chemicals indicate that the Well continues to clean up lost drilling fluid and stabilise.
The Company is adopting a prudent approach, gradually increasing production to establish a sustainable flow rate as the Well cleans up.
Mothercare (MTC.L) 18p £67.49m
The specialist global retailer for parents and young children, issued the following trading update, covering the 15-week period to 13th July 2019
Progress made in creating the optimal structure for UK retail operations as an independent Mothercare UK franchise
Revised expectation that the medium-term outlook for the UK market will continue to be uncertain and volatile, accompanied by fragile consumer confidence.
Underlying full-year PBT is forecast to be broadly comparable to the prior year, inclusive of an estimated negative impact of £2m of adopting IFRS16.
International: Growth in the key markets of India +5.5%, Indonesia +10.5% and Russia +3.4%, offset by retail sales decline in the Middle East of 11.1%
Shield Therapeutics (STX.L) 158.5p £121.19m
The “commercial stage, pharmaceutical company with a focus on addressing iron deficiency, announced that the U.S. FDA has approved its lead product Feraccru® / Accrufer® for the treatment of iron deficiency in adults.”
Shearwater Group (SWG.L) 1.9p £42m
The organisational resilience group, announced that its group company Xcina Consulting has won a multi-year contract to deliver a qualified security assessment of Parkmobile’s UK and NL card data environment to ensure that its business is compliant with the Payment Card Industry Data Security Standard.
Parkmobile, part of the BMW Group, specialises in electronic and digital parking solutions. It serves over 22 million customers in more than 1,000 towns and cities internationally. In the UK, it operates in over 70 towns and cities and processes in excess of 80 million card payments pa.
Begbies Traynor (BEG.L) 75p £89.33m
The business recovery, financial advisory and property services consultancy, announced a proposed placing to raise gross proceeds of up to £8.3m at 75p. The Company intends to use the net proceeds of the Placing to fund acquisition opportunities.
Versarien (VRS.L) 128.5p £197.8m
The advanced materials engineering group, announced that it has signed a Letter of Intent with the Company’s textile sector collaboration partner covering the initial launch of high performance sportswear incorporating Versarien’s graphene ink technology.
The Partner, who has a collaboration agreement with the Company, as announced on 8 Jan 2018, is headquartered in Asia and designs, develops and manufactures a range of different garments for well-known apparel brands globally.
Safestyle (SFE.L) 65.8p £54.48m
The retailer and manufacturer of PVCu replacement windows and doors to the UK homeowner market, issued a trading update for the six months ended 30 June 2019, in advance of its half year results announcement scheduled for 19 Sept 2019.
Since the Group’s AGM Statement on 16 May 2019, management has continued to make progress on Phase Two of its Turnaround Plan which is focused on recovering volumes and market share, restoring operational effectiveness, reducing costs and enhancing margins. As expected, the first half of the year will result in a small loss, but despite a challenging market where consumer demand appears soft, the Group remains on track to deliver a small profit for the full year which is in line with current market expectations.
In the first half of the year, the Group continued to rebuild its order book and as a result, revenues for the period will be c.£64.4m, 6.4% higher than H1 2018 with May and June being c.15% higher than the same months in 2018.
Remote Monitored Systems (RMS.L) 0.62p £2.22m
The survey, inspection and monitoring company, announced an update on its GyroMetric Systems Limited business where it owns 58%. “GyroMetric’s products are gaining considerable interest in several markets – marine drive systems, oil & gas, and wind turbines – and a growing installed base in the first of these. These expressions of interest vary from strategic applications at the heart of large corporate developments to immediate needs for specific problems to be solved. What they have in common is that the potential customers are very large corporations which move relatively slowly even when the problem is immediate and budget is available. A little more than 18 months ago GyroMetric moved out from its first customer base in marine drives where it had strong validation of its products in mission critical applications, to develop interest in much larger markets at a very senior level. This has been particularly effective in the offshore wind turbine market but these projects take time to develop.”
Marine drives— new orders for new-build installations for the company’s longest standing end customer.
Oil & Gas— contract with a well-known UK industrial group to provide test instrumentation at their facilities and this is on track for delivery by Sept.
Wind—ongoing appraisals with two major turbine producers.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.